Raymond James analyst Jayson Bedford raised the firm’s price target on Boston Scientific (BSX) to $122 from $119 and keeps a Strong Buy rating ...
Truist analyst Richard Newitter raised the firm’s price target on Boston Scientific (BSX) to $120 from $110 and keeps a Buy rating on the ...
Boston Scientific is reaping the rewards from the energised PFA market opportunity in atrial fibrillation treatment.
Q4 2024 Earnings Call Transcript February 5, 2025 Operator: Good morning, and welcome to the Boston Scientific Fourth Quarter 2024 Earnings Call. [Operator Instructions] Please note this event is ...
A federal judge in Boston will consider a request from 18 states to block President Donald Trump’s executive order ending ...
On April 21, two Burlington, Massachusetts residents are running to defy cancer as a member of the Dana-Farber Marathon ...